13 results
424B3
IKT
Inhibikase Therapeutics Inc
4 Apr 23
Prospectus supplement
4:57pm
or Latino
Race
Black or African American
White
Other
Adverse events
6, none clinically significant, only 3 possibly drug related
12, none clinically
POS AM
u4p1tfi30jssxejphs9
31 Mar 23
Prospectus update (post-effective amendment)
4:11pm
8-K
EX-99.1
ic9nf
16 Sep 22
Regulation FD Disclosure
4:09pm
8-K
EX-99.1
rufloz6c5i14k7xjew
15 Aug 22
Regulation FD Disclosure
5:12pm
8-K
EX-99.1
8ipcaojy7ef5uc 56
21 Apr 22
Regulation FD Disclosure
4:19pm
8-K
EX-99.1
u1yo ww3v44
24 Mar 22
Regulation FD Disclosure
9:17am
8-K
EX-99.1
dhu7h1kpkej
20 Jan 22
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson’s and Related Disorders 1Q 2022 BUSINESS PRESENTATION IKT
4:10pm
8-K
EX-99.1
u8dy34xhzavoo
19 Oct 21
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson’s and Related Disorders 4Q 2021 BUSINESS PRESENTATION IKT
5:03pm
- Prev
- 1
- Next